Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR2 | P21452 | 3/20 | 0.43 |
| ▸ | NT5E | P21589 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 8/20 | 0.41 |
| ▸ | CDC25B | P30305 | 8/20 | 0.41 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.39 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.39 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.39 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.39 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.39 |
| ▸ | PTPN2 | P17706 | 4/20 | 0.39 |
| ▸ | PTPN6 | P29350 | 4/20 | 0.39 |
| ▸ | PTPN11 | Q06124 | 4/20 | 0.39 |
| ▸ | TNF | P01375 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13498634 | 0.94 | PTPN1 (0.45) | TACR2NT5EPTPN1CDC25BSSTR1 | |
| SCHEMBL8701595 | 0.83 | HTR1A (0.47) | TACR2NT5EPTPN1CDC25BSSTR1 | |
| SCHEMBL4951310 | 0.83 | HTR1A (0.47) | TACR2NT5EPTPN1CDC25BSSTR1 | |
| SCHEMBL13499127 | 0.79 | TNF (0.36) | TACR2SSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL13498635 | 0.77 | TACR2 (0.41) | TACR2NT5EPTPN1CDC25BSSTR1 | |
| SCHEMBL38652098 | 0.76 | PTPN1 (0.49) | TACR2NT5EPTPN1CDC25BSSTR1 | |
| SCHEMBL13499131 | 0.75 | TNF (0.40) | NT5EPTPN1CDC25BSSTR1SSTR2 | |
| SCHEMBL28516242 | 0.73 | NT5E (0.60) | TACR2NT5EPTPN1CDC25BSSTR1 | |
| SCHEMBL13498633 | 0.73 | SSTR1 (0.43) | NT5EPTPN1CDC25BSSTR1SSTR2 | |
| SCHEMBL13498632 | 0.73 | SSTR1 (0.43) | NT5EPTPN1CDC25BSSTR1SSTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100041869-A1 | IONIC LIQUID SUPPORTED SYNTHESIS | MCGILL UNIVERSITY (CA) | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041869-A1 | IONIC LIQUID SUPPORTED SYNTHESIS | IGF2BP1, IGF2BP2, IGF2BP3 | TACR2 4393/4885NT5E 2344/4885PTPN1 4341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.